Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ESMO 2021
Pharma
Opdivo-Yervoy, Bavencio fail in head and neck cancer
Opdivo and Yervoy failed in front-line patients with recurrent or metastatic tumors, while Bavencio flopped in locally advanced disease.
Angus Liu
Sep 20, 2021 7:30am
Regeneron, Sanofi post competitive Libtayo data in 1L NSCLC
Sep 19, 2021 11:30am
Opdivo-Yervoy flops 2 stomach cancer trials
Sep 19, 2021 9:05am
Can Novartis challenge Pfizer with new breast cancer win?
Sep 19, 2021 7:30am
Merck's Keytruda cuts risk of death by 27% in TNBC
Sep 19, 2021 7:30am
Merck details Keytruda's 'practice-changing' cervical cancer win
Sep 18, 2021 9:05am
